Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07751614

Probiotic Research for Mental Health in Adult Volunteers

This randomized, double-blind, placebo-controlled pilot study will evaluate the effects of four weeks of supplementation with a probiotic on mental health in healthy adults aged 18-30 years. Participants will be randomized to receive either probiotic or placebo and will complete study assessments at baseline and end of intervention, and will complete a range of behavioral, physiological, and questionnaire-based assessments before and after the intervention. The primary objective is to assess the effect on emotional reactivity measured in a virtual reality scenario at the end of the intervention. This exploratory study is intended to generate data to inform future clinical research.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-30 years of age
  • Native-level Danish language skills
  • No current psychiatric illness, confirmed with the Presence State Examination (PSE) and the Standardized Assessment of Personality (SAPAS)
  • No previous history of severe psychiatric illness, including bipolar disorder, recurrent unipolar depression, psychosis spectrum disorders, personality disorders, autism spectrum disorders, or attention deficit (hyperactivity) disorder (ADHD/ADD), confirmed with PSE and SAPAS. Participants may still be included if they have a history of a single depressive episode, or have experienced symptoms of anxiety, stress, or burnout more than 6 months ago.

Exclusion criteria

  • Recent use of probiotics (within the past 4 weeks)
  • Use of antibiotics within the past 3 months
  • Smoking, chewable tobacco, vaping, or use of other nicotine products
  • Neurological disorders (including dementia)
  • Use of psychotropic medication within the previous 6 months, including:
  • Anxiolytics
  • Antidepressants
  • Antipsychotics
  • Anticonvulsants
  • Centrally acting corticosteroids
  • Opioid pain relievers
  • Hypnotics
  • Prescribed sleep medications or herbal sleep aids (e.g., valerian)
  • Dyslexia
  • Severe physical illness, including:
  • Cardiovascular disease
  • Diabetes
  • Gastrointestinal pathology (e.g., colon cancer, colitis, Crohn's disease)
  • Gynecological pathology (e.g., endometriosis)
  • Urologic pathology (e.g., prostate cancer)
  • Severely immunocompromised status, including:
  • HIV positive
  • Being a transplant recipient
  • Use of anti-rejection medication
  • Use of steroids for more than 30 days
  • Chemotherapy or radiotherapy within the last year
  • Current alcohol or substance abuse disorder
  • Previous severe head trauma
  • History of epilepsy
  • Pregnancy or breastfeeding
  • Known allergy to any component of the test product
  • Participation in a clinical study with another investigational product within 60 days before screening, or plans to participate in another study during the study period
  • Significant change in dietary habits within the previous 4 weeks (e.g., starting a fibre-enriched diet)
  • Planned major changes in diet or exercise habits during the study period
  • Current pregnancy

Treatment and study plan

Probiotic

Dietary Supplement

Participants will be instructed to take one capsule once daily in the morning with a meal and water.

Placebo

Dietary Supplement

Participants will be instructed to take one capsule once daily in the morning with a meal and water.

Primary outcomes

  1. VIRDIS: Rating of unpleasantness in a virtual reality social scenario

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Participants complete a virtual reality-based assessment (VIRDIS) and rate their level of unpleasantness following exposure to a predefined social scenario. Unpleasantness is assessed on a 5-point scale ranging from 1 (not at all unpleasant) to 5 (very unpleasant).

Secondary outcomes

  1. VIRDIS: a composite score of ratings of unpleasantness across all virtual reality scenarios

    Time frame: This outcome is assessed only at treatment completion (at week 4)

    This outcome comprises the mean unpleasantness score across all VR scenarios in the VIRDIS test on a scale ranging from 1 (not at all unpleasant) to 5 (very unpleasant).

  2. VIRDIS: heart rate

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Heart rate is measured during the VIRDIS assessment (using a wearable physiological monitoring device). Heart rate (pulse) is reported in beats per minute (bpm). Higher scores indicating higher heart rate.

  3. Short Form 36 - Energy/Vitality subscale

    Time frame: Change from baseline to treatment completion (at week 4)

    The SF-36 questionnaire will be administered in its entirety. The Energy/Vitality subscale (items 23, 27, 29, and 31) is designated as a secondary outcome measure.

Other outcomes

  1. VIRDIS: heart rate variability

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Heart rate variability is measured during the VIRDIS assessment (using a wearable physiological monitoring device). HRV is derived from the variation in time between consecutive heartbeats (interbeat intervals).

  2. VIRDIS: galvanic skin response

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Skin conductance (electrodermal activity) measured during the VIRDIS assessment. Outcomes include tonic and phasic skin conductance measures reported in microsiemens (µS).

  3. VIRDIS: pupil dilation

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Pupil dilation is measured during the VIRDIS assessment using integrated eye-tracking technology. The outcome is reported as change in pupil diameter (mm).

  4. VIRDIS: gaze velocity

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Eye-tracking technology integrated into the VIRDIS assessment records gaze behavior during the virtual reality scenarios. This outcome is reported as the mean gaze velocity (°/s), i.e., average angular velocity of eye movements recorded throughout the virtual reality assessment. Unit of measure: degrees/second (°/s).

  5. VIRDIS: saccade amplitude

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Eye-tracking technology integrated into the VIRDIS assessment records mean saccade amplitude in the virtual reality scenarios measures as the average angular distance of saccadic eye movements (i.e., rapid eye movement between two points of focus). Unit of measure: degrees

  6. Short Form 36

    Time frame: Change from baseline to treatment completion (at week 4).

    The SF-36 is a self-administered quality of life questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as physical component summary and mental component summary. The norm data is 0-100, the health-related quality of life increases as the scores increase. The average score is 50.

  7. European Quality of Life - 5 Dimensions (EQ-5D)

    Time frame: Change from baseline to treatment completion (at week 4).

    Questionnaire on quality of life. Part A score range: 5-15. Part B: VAS scale: 0-100.

  8. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire assessing subjective sleep quality. Outcomes include the global PSQI score (range 0-21) and the seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Higher scores indicate poorer sleep quality.

  9. Perceived Stress Scale (PSS)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on perceived stress. Score range 0-40.

  10. Major Depression Inventory (MDI)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on depressive symptoms. Score range 0-72.

  11. Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on cognitive difficulties. Score range 0-48.

  12. State-Trait Anxiety Inventory Questionnaire (STAI)

    Time frame: Change from baseline to treatment completion (at week 4).

    Questionnaire on anxiety. Score range 20-80.

  13. Attentional Control Scale (ACS)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on attentional control. Score range 12-48.

  14. Emotion Regulation Questionnaire (ERQ)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on emotion regulation. Score range 7-49.

  15. Difficulties in Emotion Regulation Scale (DERS)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on emotion regulation. Score range 0-144.

  16. Cognitive Emotion Regulation Questionnaire (CERQ)

    Time frame: Change from baseline to treatment completion (at week 4)

    Questionnaire on emotion regulation. Score range 0-72.

  17. CANTAB: Paired Associates Learning (PAL)

    Time frame: This outcome is assessed only at treatment completion (at week 4)

    Computerized test assessing visuospatial memory and new learning. The main outcome is the total number of errors (incorrect boxes selected) made across all stages, adjusted to account for stages not completed.

  18. CANTAB Rapid Visual Processing

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    A computerised neuropsychological test assessing sustained attention. The outcome measure is A-prime (A'), which measures target sensitivity (sustained attention). score range 0-1.

  19. CANTAB Spatial Working Memory task

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    A computerised neuropsychological test assessing spatial working memory. The main outcome is the number of times a participant revisits a box that has already been opened and found to be empty in a specific trial.

  20. Emotional categorisation task (EMO-CAT)

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    A computerized emotional processing task in which participants categorize positive and negative personality trait words according to whether they would like or dislike being described by each characteristic. Following the categorization task, participants are asked to recall as many words as possible.

  21. Valence Bias Task

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Computerized emotional processing task assessing valence bias during evaluation of emotional facial expressions. The primary outcome is valence bias, defined as the percentage of ambiguous surprised faces rated as "bad."

  22. Social Scenarios Test

    Time frame: This outcome is assessed only at treatment completion (at week 4).

    Computerized task assessing emotional reactivity and emotion regulation in response to positive, negative, and neutral social scenarios. The outcome measure is emotional response rated on a 100-point visual analogue scale (VAS) of discomfort or pleasure.

  23. Facial Emotion Recognition Test (FERT)

    Time frame: This outcome is assessed only at treatment completion (at week 4)..

    Computerized task assessing recognition of emotional facial expressions. The outcome measure is emotion recognition accuracy, defined as the proportion of correctly identified emotional expressions.

Study contacts

Contact information is provided by the study sponsor or research team.

Andreas Elleby Jespersen, PhD

CONTACT

[email protected]

+4524979364

Kamilla Woznica Miskowiak, Professor, DMSc, DPhil

CONTACT

[email protected]

+4522771617

Sponsors and collaborators

Lead sponsor

Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Other

Registry information

Official study title

A Randomized, Placebo-Controlled Pilot Study Evaluating a Probiotic Intervention for Mental Health

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.